Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01665040




Registration number
NCT01665040
Ethics application status
Date submitted
9/08/2012
Date registered
15/08/2012
Date last updated
19/11/2020

Titles & IDs
Public title
Clinical Outcomes Study Using a New Implantable Neurostimulation System for Chronic Intractable Pain
Scientific title
Precision Spectra™ Neurostimulator System for the Treatment of Chronic Intractable Pain of the Trunk and/or Limbs
Secondary ID [1] 0 0
A5004
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Pain 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Neurostimulation device implantation

Experimental: Neurostimulation for chronic pain - Neurostimulation (spinal cord stimulation with or without peripheral nerve stimulation of the trunk) for chronic intractable pain of the trunk and/or limbs.


Treatment: Devices: Neurostimulation device implantation
Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.
Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan.
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of Subjects Satisfied With Treatment at 90 Days Post-IPG Implantation
Timepoint [1] 0 0
90-days post permanent implantation
Primary outcome [2] 0 0
Proportion of Subjects Satisfied With Treatment in a Sub-group Utilizing More Than 2 IPG Ports at 365 Days Post-IPG Implantation
Timepoint [2] 0 0
365 days post permanent implantation

Eligibility
Key inclusion criteria
- Chronic intractable pain of the trunk and/or limbs

- Documented history of trunk and/or limb pain of at least 180 days

- Overall pain intensity of at least 5 on a 0-10 numerical rating scale (OPI-NRS-11)
over the past 180 days based on subject recall

- Pass study site's routine psychological/psychiatric evaluation within 180 days before
signing the informed consent

- Subject is willing and able to comply with all protocol-required follow-up evaluations

- 18 years of age or older when written informed consent is obtained

- Subject signs informed consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Unable to operate the Precision Spectra™ System either by self or with a caregiver

- Primary source of pain is cancer-related, pelvic, visceral, anginal or migraine

- Overall pain intensity of always 10 on a 0-10 numerical rating scale (OPI-NRS-11) over
the past 180 days based on subject recall

- Is a high surgical risk

- Currently on any anticoagulant medications that cannot be discontinued during
perioperative period

- Subject requires Magnetic Resonance Imaging (MRI) while implanted with lead(s) and/or
the Precision Spectra IPG

- Subject is participating (or intends to participate) in another investigational drug
or device clinical trial that may influence the data that will be collected for this
study

- Subjects already implanted with an active implantable device(s) to treat their pain
(IPGs, implantable drug pumps, etc) or pacemaker or Implantable Cardiac Defibrillator

- Patient is a woman who is pregnant (a urine pregnancy test must be performed within 7
days prior to the stimulation trial procedure in women of child-bearing potential) or
nursing or intends to become pregnant during the course of the trial.

- Failed to achieve satisfactory relief during the stimulation trial phase

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2014
Sample size
Target
Accrual to date
Final
40
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Metro Spinal Clinic - Caulfield
Recruitment hospital [2] 0 0
Hunter Clinical Research - Melbourne
Recruitment postcode(s) [1] 0 0
- Caulfield
Recruitment postcode(s) [2] 0 0
- Melbourne
Recruitment outside Australia
Country [1] 0 0
Belgium
State/province [1] 0 0
Roeselare
Country [2] 0 0
Spain
State/province [2] 0 0
Madrid
Country [3] 0 0
Spain
State/province [3] 0 0
Valencia

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boston Scientific Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to investigate patient satisfaction with treatment
using a new implantable neurostimulation system for chronic pain of the trunk and/or limbs.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01665040
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Roshini Jain
Address 0 0
Boston Scientific Neuromodulation Corporation
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01665040